Loading...

MedXY AI/MedXY News/Tag: targeted therapy

MedXY News

EnglishTag

targeted therapy

41 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

A BMJ systematic review and network meta‑analysis of 60 studies (4,633 patients) finds doublet chemotherapy combined with anti‑EGFR/BRAF therapy offers the best first‑line overall survival for advanced BRAF‑mutant colorectal cancer; anti‑EG

Section: GastroenterologyNov 21, 2025

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

Section: newsNov 1, 2025

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

This article reviews recent clinical trial data showing sevabertinib’s efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

Section: newsOct 26, 2025

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

Section: newsOct 26, 2025

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

Section: OncologyOct 26, 2025

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Section: OncologyOct 25, 2025

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Section: Diabetes & EndocrinologyOct 25, 2025

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.

Section: OB/GYN & Women's HealthOct 25, 2025

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.

Section: Internal MedicineOct 19, 2025

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Section: NephrologyOct 17, 2025

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

Section: newsOct 15, 2025

$Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial$

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with li

Section: Clinical UpdatesOct 9, 2025

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against app

Section: Clinical UpdatesOct 7, 2025

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and

Section: Clinical UpdatesOct 7, 2025

Pemigatinib: A Breakthrough Targeted Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements

Pemigatinib: A Breakthrough Targeted Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements

Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.

Section: Hematology-OncologyOct 6, 2025

Harnessing Exosomes in Neurodegenerative Diseases: Therapeutic Promise and Modification Techniques

Harnessing Exosomes in Neurodegenerative Diseases: Therapeutic Promise and Modification Techniques

Exosomes, nanoscale vesicles capable of crossing the blood–brain barrier, hold significant potential as targeted therapeutic agents and diagnostic markers in neurodegenerative diseases. Advances in genetic, chemical, and nanomaterial modifi

Section: NeurologyOct 5, 2025

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.

Section: Clinical UpdatesOct 1, 2025

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV60

Section: Clinical UpdatesAug 4, 2025

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Section: newsOct 1, 2025

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Section: Clinical UpdatesOct 1, 2025

Prev 1 2 3 Next